The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Oncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Mechanisms and consequences of activation of protein kinase B/Akt
Downward, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80149-x · Cited by 1,303
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
SEHGAL, S. N., BAKER, H., & VÉZINA, C. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.727 · Cited by 947
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440427 · Cited by 932
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase
Chung, J., Grammar, T. C., Lemon, K. P., Kazlauskas, A., & Blenis, J. (1994) · Nature · doi:10.1038/370071a0 · Cited by 719
Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15587 · Cited by 674
The mRNA 5′ cap-binding protein eIF4E and control of cell growth
Sonenberg, N., & Gingras, A.-C. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673
Purification and characterization of phosphoinositide 3-kinase from rat liver.
Carpenter, C. L., Duckworth, B. C., Auger, K. R., Cohen, B., Schaffhausen, B. S., & Cantley, L. C. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45429-9 · Cited by 627
Ras-Dependent Induction of Cellular Responses by Constitutively Active Phosphatidylinositol-3 Kinase
Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., & Williams, L. T. (1995) · Science · doi:10.1126/science.7701328 · Cited by 548
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
Self-citationRegulation of eIF-4E BP1 Phosphorylation by mTOR
Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 527
(1998) · PubMed · Cited by 525
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., & Lawrence, J. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7772 · Cited by 479
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342
Hu, L., Zaloudek, C. J., Mills, G. B., Gray, J. W., & Jaffe, R. B. (2000) · PubMed · Cited by 301
Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action
Sehgal, S. N. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00019 · Cited by 279
Rosenwald, I. B., Kaspar, R., Rousseau, D., Gehrke, L., Leboulch, P., Chen, J.-J., Schmidt, E. V., Sonenberg, N., & London, I. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.21176 · Cited by 269
Koltin, Y., Faucette, L., Bergsma, D. J., Levy, M. A., Cafferkey, R., Koser, P. L., Johnson, R. K., & Livi, G. P. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.3.1718 · Cited by 249
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209
Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1281 · Cited by 204
Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells
Hosoi, H., Dilling, M. B., Liu, L. N., Danks, M. K., Shikata, T., Sekulic, A., Abraham, R. T., Lawrence, J. C., & Houghton, P. J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.5.815 · Cited by 172
Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.
BAKER, H., SIDOROWICZ, A., SEHGAL, S. N., & VÉZINA, C. (1978) · The Journal of Antibiotics · doi:10.7164/antibiotics.31.539 · Cited by 166
Wiederrecht, G. J., Sabers, C. J., Brunn, G. J., Martin, M. M., Dumont, F. J., & Abraham, R. T. (1995) · Progress in Cell Cycle Research · doi:10.1007/978-1-4615-1809-9_5 · Cited by 164
RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS
Muthukkumar, S., Ramesh, T., & Bondada, S. (1995) · Transplantation · doi:10.1097/00007890-199508000-00010 · Cited by 142
Morice, W. G., Wiederrecht, G., Brunn, G. J., Siekierka, J. J., & Abraham, R. T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41589-x · Cited by 139
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis
Besson, A., Robbins, S. M., & Yong, V. W. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00542.x · Cited by 130
Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target
Sausville, E. A., Zaharevitz, D. W., Gussio, R., Meijer, L., Leost, M., Kunick, C., Schultz, R. J., Lahusen, T. J., Headlee, D. J., & Stinson, S. F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00062-x · Cited by 117
The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell Lines
Kawamata, S., Sakaida, H., Hori, T., Maeda, M., & Uchiyama, T. (1998) · Blood · doi:10.1182/blood.v91.2.561 · Cited by 117
Role of PI 3-kinase in mitogenesis
Varticovski, L., Harrison-Findik, D. D., Keeler, M. L., & Šuša, M. (1994) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(94)90051-5 · Cited by 98
Casagrande, F., Bacqueville, D., Pillaire, M., Malecaze, F., Manenti, S., Breton, M., & Darbon, J.-M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00043-x · Cited by 85
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells
Fruman, D. A., Wood, M. A., Gjertson, C. K., Katz, H. R., Burakoff, S. J., & Bierer, B. E. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250239 · Cited by 72
Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz, L. M., & Pegg, A. E. (1998) · PubMed · Cited by 61
The Monitoring of Immunosuppressive Drugs: A Pharmacodynamic Approach
Yatscoff, R. W., & Aspeslet, L. J. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199810000-00002 · Cited by 44
Petritsch, C. K., Woscholski, R., Edelmann, H. M. L., & Ballou, L. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.44.26619 · Cited by 32
Cited by
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Targeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Metadata
- Authors
- Hidalgo, M., & Rowinsky, E. K.
- Venue
- Oncogene
- Published
- 2000-12-27
- Volume
- 19
- Issue
- 56
- Pages
- 6680-6686
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2011485783
- Cited by
- 582
- References
- 50
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.